- Home
- CLLS vs SOPH Comparison
CLLS vs SOPH Comparison
Compare CLLS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | SOPH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 367.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | SOPH |
|---|---|---|
| Price | $3.12 | $4.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | $7.00 |
| AVG Volume (30 Days) | 48.3K | ★ 100.3K |
| Earning Date | 03-19-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $2.58 |
| 52 Week High | $5.48 | $5.70 |
Technical Indicators
Market Signals| Indicator | CLLS | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 44.60 |
| Support Level | $2.49 | $4.54 |
| Resistance Level | $3.22 | $4.86 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.00 | 24.26 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.